تغییر ساختاری #قشرمخ در مواجهه با #دیستایمی (اختلال #افسردگی #خفیف/#ملال)
Evidence for #neuroplastic compensation in the #cerebral #cortex of persons with #depressive illness
پژوهش های جدید نشان داده اند که #ساختار قشر مخ در افراد دارای افسردگی خفیف (دیستایمی) متفاوت از افراد غیر افسرده است و این تفاوت با #دارودرمانی مناسب برطرف می شود.
در افراد دارای دیستایمی ضخامت قشر مخ نسبت به افراد عادی بیشتر می شود (#هایپرتروفی #کرتکس) که در این پژوهش با #Duloxetine بعنوان دارودرمانی، کاهش ضخامت به اندازه عادی در این افراد در دوره 10 هفته ای مشاهده شد.
Abstract
We yoked #anatomical #brain magnetic resonance imaging (#MRI) to a #randomized, #double-blind, #placebo-#controlled trial (#RCT) of #antidepressant medication for 10-week’s duration in patients with #dysthymia. The RCT study design mitigated ascertainment bias by randomizing patients to receive either #duloxetine or #placebo, and it supported true causal inferences about treatment effects on the brain by controlling treatment assignment experimentally. We acquired 121 #anatomical #scans: at #baseline and end point in 41 patients and once in 39 healthy controls. At baseline, patients had diffusely thicker cortices than did healthy participants, and patients who had thicker cortices had proportionately less severe symptoms. During the trial, symptoms improved significantly more in medication—compared with placebo-treated patients; concurrently, thicknesses in medication-treated patients declined toward values in healthy controls, but they increased slightly, away from control values, in placebo-treated patients. Changes in symptom severity during the trial mediated the association of treatment assignment with the change in thickness, suggesting that the beneficial effects of medication on symptom severity were at least partially responsible for normalizing cortical thickness. Together our findings suggest that baseline cortical #hypertrophy in medication-free patients likely represented a compensatory, #neuroplastic #response that attenuated symptom severity. #Medication then reduced symptoms and lessened the need for compensation, thereby normalizing thickness. This is to the best of our knowledge the first study to report within an RCT a differential change in cortical morphology during medication treatment for depressive illness and the first to provide within an RCT in #vivo evidence for the presence of #neuroanatomical #plasticity in humans.
لینک منبع 👇🏻(read more)👇🏻
http://www.nature.com/mp/journal/vaop/ncurrent/full/mp201734a.html
✅(در صورت جذابیت و علاقمندی به موضوع، مطلب را برای دیگران نیز بازنشر فرمایید).
📢کانال #دکترامیرمحمدشهسوارانی
🍃🌹🌸💐🌸🌹🍃
@DrAmirMohammadShahsavarani
Evidence for #neuroplastic compensation in the #cerebral #cortex of persons with #depressive illness
پژوهش های جدید نشان داده اند که #ساختار قشر مخ در افراد دارای افسردگی خفیف (دیستایمی) متفاوت از افراد غیر افسرده است و این تفاوت با #دارودرمانی مناسب برطرف می شود.
در افراد دارای دیستایمی ضخامت قشر مخ نسبت به افراد عادی بیشتر می شود (#هایپرتروفی #کرتکس) که در این پژوهش با #Duloxetine بعنوان دارودرمانی، کاهش ضخامت به اندازه عادی در این افراد در دوره 10 هفته ای مشاهده شد.
Abstract
We yoked #anatomical #brain magnetic resonance imaging (#MRI) to a #randomized, #double-blind, #placebo-#controlled trial (#RCT) of #antidepressant medication for 10-week’s duration in patients with #dysthymia. The RCT study design mitigated ascertainment bias by randomizing patients to receive either #duloxetine or #placebo, and it supported true causal inferences about treatment effects on the brain by controlling treatment assignment experimentally. We acquired 121 #anatomical #scans: at #baseline and end point in 41 patients and once in 39 healthy controls. At baseline, patients had diffusely thicker cortices than did healthy participants, and patients who had thicker cortices had proportionately less severe symptoms. During the trial, symptoms improved significantly more in medication—compared with placebo-treated patients; concurrently, thicknesses in medication-treated patients declined toward values in healthy controls, but they increased slightly, away from control values, in placebo-treated patients. Changes in symptom severity during the trial mediated the association of treatment assignment with the change in thickness, suggesting that the beneficial effects of medication on symptom severity were at least partially responsible for normalizing cortical thickness. Together our findings suggest that baseline cortical #hypertrophy in medication-free patients likely represented a compensatory, #neuroplastic #response that attenuated symptom severity. #Medication then reduced symptoms and lessened the need for compensation, thereby normalizing thickness. This is to the best of our knowledge the first study to report within an RCT a differential change in cortical morphology during medication treatment for depressive illness and the first to provide within an RCT in #vivo evidence for the presence of #neuroanatomical #plasticity in humans.
لینک منبع 👇🏻(read more)👇🏻
http://www.nature.com/mp/journal/vaop/ncurrent/full/mp201734a.html
✅(در صورت جذابیت و علاقمندی به موضوع، مطلب را برای دیگران نیز بازنشر فرمایید).
📢کانال #دکترامیرمحمدشهسوارانی
🍃🌹🌸💐🌸🌹🍃
@DrAmirMohammadShahsavarani